STOCK TITAN
  1. Home
  2. Sec-filings
  3. RVMD
  4. [Form 4] Revolution Medicines, Inc. Insider Trading Activity

RVMD General Counsel's Stock Sale Tied to Tax Obligations, Retains 56K Shares

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Revolution Medicines (RVMD) General Counsel Jeff Cislini reported insider trading activity on June 16, 2025. The transaction involved the sale of 1,878 shares at a weighted average price of $39.83 per share, executed through multiple trades ranging from $39.5915 to $39.8291.

The sale was conducted under a Rule 10b5-1 trading plan established on May 31, 2023, specifically to cover tax withholding obligations related to vesting restricted stock units (RSUs). Following the transaction, Cislini's holdings include:

  • Total beneficial ownership of 56,005 shares
  • 49,054 RSUs included in total holdings
  • 160 shares acquired through Employee Stock Purchase Plan on May 31, 2025

This transaction demonstrates a planned, automated sale for tax purposes rather than a discretionary trading decision by the insider.

Positive

  • None.

Negative

  • None.
Insider Cislini Jeff
Role General Counsel
Sold 1,878 shs ($75K)
Type Security Shares Price Value
Sale Common Stock 1,878 $39.83 $75K
Holdings After Transaction: Common Stock — 56,005 shares (Direct)
Footnotes (1)
  1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. This transaction was executed in multiple trades in prices ranging from $39.5915 to $39.8291, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Includes 160 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2025. Includes 49,054 RSUs.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cislini Jeff
(Last) (First) (Middle)
C/O REVOLUTION MEDICINES, INC.
700 SAGINAW DRIVE
(Street)
REDWOOD CITY CA 94063
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
General Counsel
3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/16/2025 S(1) 1,878 D $39.83(2) 56,005(3)(4) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.
2. This transaction was executed in multiple trades in prices ranging from $39.5915 to $39.8291, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
3. Includes 160 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2025.
4. Includes 49,054 RSUs.
/s/ Jack Anders, as Attorney-in-fact for Jeff Cislini 06/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

How many RVMD shares did General Counsel Jeff Cislini sell on June 16, 2025?

Jeff Cislini sold 1,878 shares of RVMD common stock on June 16, 2025 at a weighted average price of $39.83 per share.

What was the purpose of RVMD General Counsel's stock sale in June 2025?

The stock sale was made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023, specifically to satisfy tax withholding obligations upon the vesting of restricted stock units (RSUs) after July 15, 2023.

How many RVMD shares does Jeff Cislini own after the June 2025 transaction?

Following the transaction, Jeff Cislini beneficially owns 56,005 shares, which includes 49,054 RSUs and 160 shares acquired through the Employee Stock Purchase Plan on May 31, 2025.

What was the price range of RVMD shares sold by Jeff Cislini in the June 2025 transaction?

The shares were sold in multiple trades at prices ranging from $39.5915 to $39.8291 per share, with a weighted average sale price of $39.83.